Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Predictive genetic tool developed to better inform men whether and when to take PSA blood test.

Predictive genetic tool developed to better inform men whether and when to take PSA blood test.

Prostate cancer detection currently relies on the prostate-specific antigen (PSA) screening blood test, which has been proven to reduce deaths from the disease. However, PSA testing is a poor screening tool because it can also produce false positive results and encourages over-detection of non-aggressive, slow-growing tumors.

An international team has now developed a genetic tool that has been proven to be able to predict the age of onset of aggressive prostate cancer, a disease that kills more than 26,000 American men annually.

The new tool may potentially be used to guide decisions about who to screen for prostate cancer and at what age.

The team used genome-wide association studies (GWAS) to determine whether a man’s genetic predisposition to developing prostate cancer could be used to predict his risk of developing the aggressive and lethal form of the disease.

GWAS search individual genomes for small variations, called single-nucleotide polymorphisms (SNPs), that occur more frequently in people with a particular disease than in people without the disease. Hundreds or thousands of SNPs can be evaluated at the same time in large groups of people. In this case, researchers used data from over 200,000 SNPs from 31,747 men of European ancestry participating in the ongoing international PRACTICAL consortium project.

Genotype, prostate cancer status and age were analyzed to select SNPs associated with prostate cancer diagnosis. Then the data was incorporated into a new prediction tool, the Polygenic Hazard Score, which involves survival analysis to estimate SNPs’ effects on age at diagnosis of aggressive prostate cancer. The results led to a Polygenic Hazard Score for Prostate Cancer that can estimate individual genetic risk. The Polygenic Hazard Score was then further tested on an independent dataset from the ProtecT study centered at the Nuffield Department of Surgical Sciences.

Ian Mills, John Black Associate Professor of Prostate Cancer at the Nuffield Department of Surgical Sciences, said: ‘The strength of this test is that an individual’s genotype does not change with age, so the polygenic hazard score can be calculated at any time and used as a tool for men deciding whether and when to undergo screening for prostate cancer.

‘This is particularly important for men at risk of developing prostate cancer at a very young age, before standard guidelines recommend screening.

‘However, we still need to study the clinical benefits before the polygenic hazard score is ready for routine use.’

First author on the paper, Dr Tyler Seibert of the University of California San Diego, said: ‘The polygenic hazard score was calculated from 54 SNPs and proved to be a highly significant predictor of age at diagnosis of aggressive prostate cancer.

‘When men in the ProtecT dataset with a high polygenic hazard score were compared to those with average PHS, their risk of aggressive prostate cancer was at least 2.9 times greater.

‘And when we account statistically for the effect of the GWAS having disproportionately high numbers of men with disease compared to the general population, we estimate that the risk defined by the polygenic hazard score is 4.6 times greater.’

The full paper, ‘Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large-scale cohorts’, can be read in the BMJ.

Funding for this research came, in part, the U.S. Department of Defense (grant w81xwh-13-1-0391), the Research Council of Norway, KG Jebsen Stiftelsen and South East Norway Health Authority.

Similar stories

New Cochrane evidence explores treatment options for chronic ear disease

Publication Research

A new Evidently Cochrane blog post for World Hearing Day summarises seven recent reviews on medical treatments for infection and inflammation of the middle ear.

New reporting guidelines to bridge the gap from development to implementation in clinical artificial intelligence

Innovation Research

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

Cochrane ENT awarded NIHR funding for COVID-19 project

Awards and appointments Coronavirus COVID-19 Research

Cochrane ENT at the Nuffield Department of Surgical Sciences has been awarded funding by the National Institute for Health Research (NIHR) to complete a suite of living systematic reviews investigating the effectiveness and safety of interventions to prevent and treat loss of smell after COVID-19 infection.

JNDS: new issue out now

Department Publication

Journal of the Nuffield Department of Surgical Sciences (JNDS) has published its next issue, featuring top case reports written by University of Oxford medical students during their clinical studies.

First peer-reviewed results of phase 3 human trials of Oxford coronavirus vaccine demonstrate efficacy

Coronavirus COVID-19 Publication Research

Today University of Oxford and AstraZeneca researchers present a pooled analysis of Phase 3 trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%.

Applications for Oxford-Wolfson-Marriott-Patel Scholarship now open

Awards and appointments Department Research

The Nuffield Department of Surgical Sciences (NDS) are pleased to confirm that one scholarship will be available for Home (UK) and Republic of Ireland (ROI) candidates for the DPhil in Surgical Sciences, starting in Michaelmas Term 2021.